Molecular dynamics simulation of the heterodimeric mGluR2/5HT2A complex. An atomistic resolution study of a potential new target in psychiatric conditions

Journal of Chemical Information and Modeling

Volumn 49, Issue 6, 2009, Pages 1602-1616

  Bruno, Agostino ^a   Guadix, Antonio Entrena ^b   Costantino, Gabriele ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; C (PROGRAMMING LANGUAGE); MOLECULES;

ATOMISTIC RESOLUTION; G-PROTEIN COUPLED RECEPTORS; HETERODIMERIZATION; IN-SILICO SCREENING; METABOTROPIC GLUTAMATE RECEPTORS; MOLECULAR DYNAMICS SIMULATIONS; MOLECULAR TARGETS; TRANS-MEMBRANE DOMAINS;

MOLECULAR DYNAMICS;

DIMYRISTOYLPHOSPHATIDYLCHOLINE; LIGAND; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; PSYCHEDELIC AGENT; SEROTONIN RECEPTOR;

ARTICLE; BINDING SITE; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; MENTAL DISEASE; METABOLISM; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; TIME;

BINDING SITES; CELL MEMBRANE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HALLUCINOGENS; HUMANS; LIGANDS; MENTAL DISORDERS; MODELS, MOLECULAR; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, SEROTONIN; TIME FACTORS;

EID: 67650089750     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900067g     Document Type: Article

References (60)

1. Panetta, R.; Greenwood, M. T. Physiological relevance of GPCR oligomerization and its impact on drug discovery. Drug Discovery Today 2008, 13, 1059-1066.
2. Dalrymple, M. B.; Pfleger, K. D.; Eidne, K. A. G protein-coupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol. Ther. 2008, 118, 359-371.
3. Milligan, G.; Smith, N. J. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol. Sci. 2007, 28, 615-620.
4. Bayburt, T. H.; Leitz, A. J.; Xie, G.; Oprian, D. D.; Sligar, S. G. Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins. J. Biol. Chem. 2007, 282, 14875-14881.
5. Whorton, M. R.; Bokoch, M. P.; Rasmussen, S. G.; Huang, B.; Zare, R. N.; Kobilka, B.; Sunahara, R. K. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 7682-7687.
6. Décaillot, F. M.; Rozenfeld, R.; Gupta, A.; Devi, L. A. Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 16045-16050.
7. Marshall, F. H.; Jones, K. A.; Kaupman, K.; Bettler, B. GABAB receptors - the first 7TM heterodimers. Trends Pharmacol. Sci. 1999, 20, 396-399.
8. Pin, J. P.; Galvez, T.; Prèzeau, L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther. 2003, 98, 325-354.
9. Pin, J. P.; Kniazeff, J.; Binet, V.; Liu, J.; Maurel, D.; Galvez, T.; Duthey, B.; Havlickova, M.; Blahos, J. Prèzeau L.; Rondard, P. Activation mechanism of the heterodimeric GABA(B) receptor. Biochem. Pharmacol. 2004, 68, 1565-1572.
10. Brock, C.; Oueslati, N.; Soler, S.; Boudier, L.; Rondard, P.; Pin, J. P. Activation of a dimeric metabotropic glutamate receptor by intersubunit rearrangement. J. Biol. Chem. 2007, 282, 33000-33008.
11. Gonzàlez-Maeso, J.; Ang, R. L.; Yuen, T.; Chan, P.; Weisstaub, N. V.; Lòpez-Gimènez, J. F.; Zhou, M.; Okawa, Y.; Callado, L. F.; Milligan, G.; Gingrich, J. A.; Filizola, M.; Meana, J. J.; Sealfon, S. C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452, 93-97.
12. Rorick-Kehn, L. M.; Johnson, B. G.; Burkey, J. L.; Wright, R. A.; Calligaro, D. O.; Marek, G. J.; Nisenbaum, E. S.; Catlow, J. T.; Kingston, A. E.; Giera, D. D.; Herin, M. F.; Monn, J. A.; McKinzie, D. L.; Schoepp, D. D. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0] -hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2007, 321, 308-317.
13. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009, 30, 25-31.
14. Gonzàlez-Maeso, J.; Weisstaub, N. V.; Zhou, M.; Chan, P.; Ivic, L.; Ang, R.; Lira, A.; Bradley-Moore, M.; Ge, Y.; Zhou, Q.; Sealfon, S. C.; Gingrich, J. A. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behaviour. Neuron 2007, 53, 439-452.
15. Charles, A. C.; Mostovskaya, N.; Asas, K.; Evans, C. J.; Dankovich, M. L.; Hales, T. G. Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory. Mol. Pharmacol. 2003, 63, 89-95.
16. 4 receptor dimerization. Biochem. Biophys. Res. Commun. 2007, 356, 642-647.
17. Parravicini, C.; Ranghino, G.; Abbracchio, M. P.; Fantucci, P. GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors. BMC Bioinf. 2008, 9, 263-271.
18. Moro, S.; Spalluto, G.; Jacobson, K. A. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. Trends Pharmacol. Sci. 2005, 26, 44-51.
19. Reggio, P. H. Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers. AAPS J. 2006, 8, E322-336.
20. Costanzi, S. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J. Med. Chem. 2008, 51, 2907-2914.
21. Damian, M.; Martin, A.; Mesnier, D.; Pin, J. P.; Banères, J. L. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 2006, 25, 5693-5702.
22. Levoye, A.; Dam, J.; Ayoub, M. A.; Guillaume, J. L.; Couturier, C.; Delagrange, P.; Jockers, R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 2006, 25, 3012-3023.
23. Snyder, S. H. Neuroscience: a complex in psychosis. Nature 2008, 452, 38-39.
24. Liang, Y.; Fotiadis, D.; Filipek, S.; Saperstein, D. A.; Palczewski, K.; Engel, A. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 2003, 278, 21655-21662.
25. Kota, P.; Reeves, P. J.; Rajbhandary, U. L.; Khorana, H. G. Opsin is present as dimers in COS1 cells: identification of amino acids at the dimeric interface. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3054-3059.
26. Guo, W.; Shi, L.; Filizola, M.; Weinstein, H.; Javitch, J. A. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17495-17500.
27. Guo, W.; Urizar, E.; Kralikova, M.; Mobarec, J. C.; Shi, L.; Filizola, M.; Javitch, J. A. Dopamine D2 receptors form higher order oligomers at physiological expression levels. EMBO J. 2008, 27, 2293-2304.
28. Niv, M. Y.; Filizola, M. Influence of oligomerization on the dynamics of G-protein coupled receptors as assessed by normal mode analysis. Proteins 2008, 71, 575-586.
29. Filizola, M.; Wang, S. X.; Weinstein, H. Dynamic models of G-protein coupled receptor dimers: indications of asymmetry in the rhodopsin dimer from molecular dynamics simulations in a POPC bilayer. J. Comput.-Aided Mol. Des. 2006, 20, 405-416.
30. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
31. Li, J.; Edwards, P. C.; Burghammer, M.; Villa, C.; Schertler, G. F. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 2004, 343, 1409-1438.
32. Vanejevs, M.; Jatzke, C.; Renner, S.; Müller, S.; Hechenberger, M.; Bauer, T.; Klochkova, A.; Pyatkin, I.; Kazyulkin, D.; Aksenova, E.; Shulepin, S.; Timonina, O.; Haasis, A.; Gutcaits, A.; Parsons, C. G.; Kauss, V.; Weil, T. Positive and negative modulation of group I metabotropic glutamate receptors. J. Med. Chem. 2008, 51, 634-647.
33. Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.; McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.; Gibson, T. J.; Higgins, D. G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23, 2947-2948.
34. Chemical Computing Group. Scalable software Scalable Science. http://www.chemcomp.com (accessed Nov 3, 2008).
35. Swiss Institute of Bioinformatics. ExPASy Proteomics Server. http://www.expasy.org (accessed Jun 26, 2008).
36. Gray, J. J.; Moughon, S.; Wang, C.; Schueler-Furman, O.; Kuhlman, B.; Rohl, C. A.; Baker, D. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J. Mol. Biol. 2003, 331, 281-299.
37. Center for Structural Biology, Yale University. ROSETTA++ http://www.csb.yale.edu/userguides7datamanip/rosetta/rosetta-descrip.html (accessed Jun 10, 2008).
38. Jo, S.; Kim, T.; Iyer, V. G.; Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 2008, 29, 1859-1865.
39. Jo, S.; Kim, T.; Im, W. Automated builder and database of protein/membrane complexes for molecular dynamics simulations. PloS ONE. 2007, 2, e880.
40. Lomize, A. L.; Pogozheva, I. D.; Lomize, M. A.; Mosberg, H. I. Positioning of proteins in membranes: a computational approach. Protein Sci. 2006, 15, 1318-1333.
41. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kalè, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26, 1781-1802.
42. Alex MacKerell. MacKerell laboratory home page. http://mackerell. umaryland.edu/MacKerell-Lab.html (accessed Jul 4, 2008).
43. Humphrey, W.; Dalke, A.; Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 1996, 14, 33-38.
44. Theoretical and Computational Biophysics Group. http://www. ks.uiuc.edu/Research/vmd/plugins (accessed Jan 14, 2009).
45. Cheatham Lab. Cheatham Lab WWW page. http://www.chpc.utah.edu/~cheatham/ software.html (accessed Jan 21, 2009).
46. Amadei, A.; Linssen, A. B.; Berendsen, H. J. Essential dynamics of proteins. Proteins 1993, 17, 412-425.
47. Berk, H. Similarities between principal components of protein dynamics and random diffusion. Phys. Rev. 2000, 62, 8438-8448.
48. Mongan, J. Interactive essential dynamics. J. Comput.-Aided Mol. Des. 2004, 18, 433-436.
49. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accurancy of docking with a new scoring function, efficient optimization and multithreading. http://vina.scripps.edu (accessed March 28, 2009).
50. The Scripps Research Institute. MGL Tools. http://mgltools.scripps.edu (accessed March 28, 2009).
51. Baker, R. W.; Chothia, C.; Pauling, P.; Weber, H. P. Molecular structures of hallucinogenic substances: lysergic acid diethylamide, psilocybin, and 2,4,5-trimethoxyamphetamine. Mol. Pharmacol. 1973, 9, 23-32.
52. Cambridge Structural Database. http://www.ccdc.cam.ac.uk/products/csd/ (accessed March 28th, 2009).
53. Tripos. http://www.tripos.com (accessed Jan 16, 2009).
54. Kao, H. T.; Adham, N.; Olsen, M. A.; Weinshank, R. L.; Branchek, T. A.; Hartig, P. R. Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology. FEBS Lett. 1992, 307, 324-328.
55. 2A receptors. Mol. Pharmacol. 1997, 52, 259-266.
56. Roth, B. L.; Willins, D. L.; Kristiansen, K.; Kroeze, W. K. 5-Hydroxytryptamine2-familyreceptors(5-hydroxytryptamine2A, 5- hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol. Ther. 1998, 79, 231-257.
57. Shapiro, D. A.; Kristiansen, K.; Kroeze, W. K.; Roth, B. L. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol. Pharmacol. 2000, 58, 877-886.
58. Kristiansen, K.; Kroeze, W. K.; Willins, D. L.; Gelber, E. I.; Savage, J. E.; Glennon, R. A.; Roth, B. L. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a "salt-bridge disruption" mechanism. J. Pharmacol. Exp. Ther. 2000, 293, 735-746.
59. Ebersole, B. J.; Visiers, I.; Weinstein, H.; Sealfon, S. C. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5HT2A receptor determines relative efficacy. Mol. Pharmacol. 2003, 63, 36-43.
60. Braden, M. R.; Nichols, D. E. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5HT2A receptor. Mol. Pharmacol. 2007, 72, 1200-1209.